SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-20-010732
Filing Date
2020-02-19
Accepted
2020-02-19 17:35:20
Documents
2
Period of Report
2020-02-17

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1505
2 POA DOCUMENT poa.txt EX-24.3_896140 3998
  Complete submission text file 0001209191-20-010732.txt   7185
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Issuer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 6TH FLOOR NEW YORK NY 10018
Business Address
Venker Eric (Reporting) CIK: 0001801917 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37418 | Film No.: 20631442